Researchers identify potential new target in war on malaria
This article was originally published in Scrip
A consortium of researchers at the universities of Nottingham, Leicester, Oxford, Imperial College London, and Leiden and the MRC National Institute for Medical Research has discovered a potential new target in the fight against malaria. The collaborators have identified a protein – CDC20 – that has a key role in the cell division cycle of the malaria parasite Plasmodium berghei and the development of microgametes, which are essential for transmission between humans and the mosquito carrier.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.